KDELR3 Is a Prognostic Biomarker Related to the Immune Infiltration and Chemoresistance of Anticancer Drugs in Uveal Melanoma

Table 1

Correlation between tissue KDELR3 expression level and clinicopathological characteristics.

Characteristic	Low expression of KDELR3	High expression of KDELR3
	40	40
Pathologic T stage, (%)			0.644
T2	8 (10%)	6 (7.5%)
T3	17 (21.2%)	15 (18.8%)
T4	15 (18.8%)	19 (23.8%)
Pathologic N stage, (%)			0.579
N0	28 (35.4%)	24 (30.4%)
NX	12 (15.2%)	15 (19%)
Pathologic M stage, (%)			0.128
M0	28 (35.9%)	23 (29.5%)
M1	0 (0%)	4 (5.1%)
MX	12 (15.4%)	11 (14.1%)
Pathologic stage, (%)			0.113
Stage II	22 (27.8%)	17 (21.5%)
Stage III	18 (22.8%)	18 (22.8%)
Stage IV	0 (0%)	4 (5.1%)
Gender, (%)			1.000
Female	17 (21.2%)	18 (22.5%)
Male	23 (28.7%)	22 (27.5%)
Age, (%)			0.502
≤60	22 (27.5%)	18 (22.5%)
>60	18 (22.5%)	22 (27.5%)
Age,			0.017